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The effect of sequence heterogeneity on the immunologic properties of two strong antigenic regions of the hepatitis C virus
(HCV) NS4 protein was studied by using a set of 443 overlapping 20-mer synthetic peptides. One antigenic region comprising
the cleavage site between NS4a and NS4b (region 5-1-1) was modeled with peptides derived from 73 different known
sequences, representing HCV genotypes 1–6. The other antigenic region, designated region 59 and located at the C-terminus
of the NS4b protein, was modeled with peptides from 7 known sequences representing genotypes 1–3. All peptides were
tested for antigenic reactivity by enzyme immunoassay with a panel of anti-HCV-positive serum specimens representing
genotypes 1–5. The data demonstrated that immunoreactive peptides fell into two groups. One group, represented by
N-terminal peptides, demonstrated genotype-independent immunoreactivity; the other group, from the central part of region
5-1-1, showed strict genotype specificity. Nineteen peptides from the genotype-independent group strongly immunoreacted
with a wide range of serum samples containing antibodies to all 5 HCV genotypes. Twenty-five peptides from the
genotype-specific group were found to strongly react with serum containing antibodies only to the genotype from which the
peptides were derived. Similar to the N-terminal part of region 5-1-1, peptides derived from region 59 did not show
genotype-specific immunoreactivity. Some peptides derived from the central part of region 59 showed very strong and broad
antigenic reactivity. Thus, after examining two antigenic regions of the NS4 protein, we identified short sequences that can
be used for the efficient detection of either genotype-independent or genotype-specific HCV antibodies.
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Hepatitis C virus (HCV) causes approximately 70% of
on-A, non-B hepatitis worldwide (Kuo et al., 1989; Choo
t al., 1989; Choo et al., 1991; Chaudhary et al., 1991). The
CV genome is represented by a single-stranded, posi-
ive-sense RNA of ;9500 nucleotides (nt) that encodes a
ingle polyprotein of ;3000 amino acids (aa) (Choo et
l., 1989, 1991; Kato, 1990; Takamizawa et al., 1991). This
olyprotein is processed by host and viral proteases into
hree structural proteins, namely, core (C), E1, and E2,
nd several nonstructural proteins, including NS2, NS3,
S4a, NS4b, NS5a, and NS5b (Miller and Purcell, 1990;
akeuchi et al., 1990; Choo et al., 1991; Hijikata et al.,
991; Takamizawa et al., 1991; Houghton et al., 1991). The
ntigenic composition of all HCV proteins was thor-
ughly studied by using recombinant proteins (Kuo et al.,
989; Chien et al., 1992; Muraiso et al., 1990; Chiba et al.,
991; Nasoff et al., 1991) and synthetic peptides (Cerino
nd Mondelli, 1991; Hosein et al., 1991; Neri et al., 1992;
allberg et al., 1992; Yuki et al., 1992; Khudyakov et al.,
1 To whom correspondence and reprint requests should be ad-
ressed at Hepatitis Branch, MS A-33, Division of Viral and Rickettsial
iseases, Centers for Disease Control and Prevention, 1600 Cliftonboad, Atlanta, GA 30333. Fax: (404) 639-1563. E-mail: yek0@cdc.gov.
177995; Simmonds et al., 1993b; Simmonds, 1995; Zhang et
l., 1994; Pujol et al., 1996). The most diagnostically
elevant antigenic epitopes were identified in the HCV C,
S3, and NS4 proteins (Kuo et al., 1989; Chien et al.,
992; Muraiso et al., 1990; Chiba et al., 1991; Hosein et
l., 1991; Nasoff et al., 1991; Sallberg et al., 1992). Differ-
nt segments of these proteins have been used as an-
igenic targets in various commercial diagnostic tests for
he detection of the anti-HCV activity in serum speci-
ens (Mori et al., 1992; Chien et al., 1992; Muraiso et al.,
990; Hosein et al., 1991; Van Der Poel et al., 1991; Inoue
t al., 1992; Riezu-Boj et al., 1992; Berasain et al., 1993).
Based on sequence heterogeneity, the HCV genome
as classified into six major genotypes (Simmonds et al.,
993a). The nucleotide sequence homology between
hese genotypes is ;70%, which is similar to that be-
ween different serotypes of other flaviviruses (Sim-
onds et al., 1993b). It has been shown by several
nvestigators that such significant nucleotide and amino
cid sequence heterogeneity affects the immunoreactiv-
ty of several HCV proteins. For example, the antigenic
eactivity of c100-3, a recombinant protein derived from
enotype 1a and composed of strong antigenic regions
f the HCV NS4 protein, with antibodies from serum of
atients infected with HCV genotype 2 or 3, was found to
e lower or even absent compared to the reactivity with
0042-6822/99
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178 CHANG ET AL.nti-HCV antibodies from serum samples from patients
nfected with HCV genotype 1 (Nagayama et al., 1993;
cOmish et al., 1993, 1994; Alonso et al., 1994; Chan et
l., 1991; Dhaliwal et al., 1996; Zein et al., 1995, 1997).
urther experiments with synthetic peptides derived from
he HCV C and NS4 proteins demonstrated the presence
f type-specific antibodies in serum specimens obtained
rom patients infected with different HCV genotypes
Machida et al., 1992; Simmonds et al., 1993b; Bhattach-
rjee et al., 1995). Because recombinant proteins and
eptides used in many commercial HCV serological di-
gnostic tests uniformly belong to genotype 1a, these
bservations have raised concerns regarding the sensi-
ivity of current serological assays in detecting antibod-
es to different HCV genotypes. Simultaneously, these
esults were used to develop serological assays that will
iscriminate HCV types, based on the specificity of an-
ibody responses to several antigenic epitopes of the
CV C and NS4 proteins (Simmonds et al., 1993b; Bhat-
acherjee et al., 1995; Zhang et al., 1995).
The HCV NS4 protein, which is the focus of the present
tudy, contains two strong antigenic regions. One region,
hich was originally designated region 5-1-1 (Choo et
l., 1989; Kuo et al., 1989), comprises the C-terminal part
f NS4a and the N-terminal part of NS4b (Grakoui et al.,
993). The other region, designated region 59, is located
t the C-terminus of the NS4b protein (Khudyakov et al.,
995; Wienhues et al., 1998). Antigenic epitopes for both
egions can be efficiently modeled with synthetic pep-
ides of different sizes (Simmonds et al., 1993b; Bhattach-
rjee et al., 1995; Khudyakov et al., 1995). The amino acid
equence of region 5-1-1 is very heterogeneous (Dush-
iko et al., 1994; Simmonds, 1995; Bukh et al., 1995).
ntigenic analysis of synthetic peptides derived from the
onsensus sequences of region 5-1-1 from genotypes 1,
, and 3 revealed that this region contains both geno-
ype-independent and genotype-specific antigenic
pitopes (Simmonds et al., 1993b). The amino acid se-
uence of region 59 is less heterogeneous than that of
he region 5-1-1 (Chamberlain et al., 1997; Stuyver et al.,
994; Adams et al., 1997). The effect of sequence heter-
geneity on the antigenic properties of this region has
ot been previously established.
The present study was designed to extend previous
bservations made for the consensus sequences of re-
ion 5-1-1 (Simmonds et al., 1993b; Simmonds, 1995) and
o determine the effect of sequence heterogeneity on the
mmunoreactivity of region 59 by analyzing all known
equences for these regions. In addition, the present
tudy was designed to identify the most diagnostically
elevant sequences within these two antigenic regions.
his paper describes the results of serological testing of
large number of overlapping synthetic peptides derived
rom 73 different known sequences of region 5-1-1, rep-
esenting genotypes 1–6, and from 7 different known
equences of region 59, representing genotypes 1–3. rome peptides derived from region 5-1-1 derived from
CV genotypes 1 and 3 but not from genotypes 2, 4, 5,
nd 6 were found to immunoreact with all tested serum
pecimens representing genotypes 1–5. Some other
eptides strictly immunoreacted with serum specimens
epresenting the genotype from which the peptide was
erived. The reactivity of peptides derived from region 59
as shown to be genotype independent. The results of
his study are important for developing new HCV diag-
ostic assays that will detect anti-HCV activity with equal
fficiency irrespective of genotype.
RESULTS AND DISCUSSION
equence analysis
Sequences of region 5-1-1 from position 1684 to 1750
a and of region 59 from position 1901 to 1960 aa were
elected for analysis. Amino acid positions are indicated
ccording to the HCV genotype 1 sequence with the
enBank Accession No. D13558 (Okamoto et al., 1992)
or region 5-1-1. The amino acid positions for region 59
re indicated based on the HCV type 3 sequence with
ccession No. D49374 (Chayama et al., 1994). For region
-1-1, 73 unique sequences representing genotypes 1–6
ere identified. For region 59, only 7 unique sequences
epresenting genotypes 1–3 were used. Three additional
equences from region 59 representing genotypes 4–6
ere deposited with GenBank only after all peptides had
een prepared and tested.
All sequences from regions 5-1-1 and 59 were com-
ared. The results of this comparison are presented in
igs. 1 and 2. Dendrograms, as shown in Figs. 3 and 4,
ere built on the basis of percentage similarity between
airs of amino acid sequences for both regions. The
endrograms demonstrate sequence grouping com-
letely consistent with genotypes, as determined by
omparison of nucleotide sequences. As can be seen in
igs. 1 and 3, the majority of sequences (n 5 52) from
egion 5-1-1 obtained from GenBank belong to genotype
, including 38 sequences from subtype 1a, 13 se-
uences from subtype 1b, and 1 sequence from subtype
c. Genotype 3 is represented by 8 sequences (7 from
ubtype 3a, 1 from subtype 3b), and genotype 2 is rep-
esented by 7 sequences (5 from subtype 2a, 2 from
ubtype 2b). Genotypes 4, 5, and 6 were represented
ith only 1 sequence each (Figs. 1 and 3). Sequences
rom region 59 used in this study belong to genotypes 1
n 5 3), 2 (n 5 2), and 3 (n 5 2).
Sequences from region 5-1-1, representing genotypes
and 4, were the most homologous. The pairwise amino
cid sequence similarity between these two genotypes
as within the range of 69.0–76.1%. Sequences from
enotypes 2 and 5 were the most divergent, varying from
2.4 to 38.0%. Sequences 54 (genotype 5a) and 65 (ge-
otype 2b) were two the most distant sequences fromegion 5-1-1 identified in this study. These two se-
a
aFIG. 1. Alignment of the region 5-1-1 amino acid sequences at position 1684–1750 aa and location of synthetic peptides. Genotypes and subtypes
re shown within the vertical black bars. Each sequence has a number shown at the beginning of the sequence. Invariant positions in all sequences
re shaded. Horizontal hollow bars marked with numbers from 1 to 13 shown above the sequences represent synthesized peptides.
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180 CHANG ET AL.uences shared only 32.4% similarity. In general, geno-
ype 2 sequences were the most different from all other
equences, with only 32.4–56.3% similarity. When amino
cid sequences were compared within the same geno-
ype, the degree of similarity was found to be as high as
6.9–98.6%. Sequences from region 59 (Fig. 2) shared
ignificantly greater similarity than sequences from re-
ion 5-1-1. The percentage pairwise similarity between
he 7 sequences from region 59 varied within a narrow
ange of 80.6–93.5%.
eptide design
All synthetic peptides were designed as overlapping
0-mers in such a way that every downstream peptide
verlapped with the adjacent upstream peptide by 16
a. Every sequence from region 5-1-1 was spanned
ith 13 overlapping peptides (Fig. 1). Every sequence
rom region 59 was spanned with 11 overlapping pep-
ides (Fig. 2). Because of identical amino acid se-
uences shared between sequences from region 5-1-1
nd those from region 59, a total of 377 peptides were
ynthesized for the sequences from region 5-1-1 and
6 peptides were synthesized for the sequences from
egion 59.
mmunoreactivity of synthetic peptides derived from
egion 5-1-1
All 377 synthetic peptides derived from 73 se-
uences from region 5-1-1 were tested with a panel of
nti-HCV positive serum samples containing antibod-
es to different HCV genotypes (see Materials and
ethods). The results of this analysis are presented in
able 1. As can be seen in this table, all of the peptides
an be assigned to one of two groups, based on their
FIG. 2. Alignment of the region 59 amino acid sequences at position
lack boxes. Each sequence has a number shown at the very beginning
ollow bars marked with numbers from 1 to 11 shown above sequencmmunoreactivity to different serum specimens from che panel. One group, designated the genotype-inde-
endent group, is composed of peptides that immuno-
eacted with serum specimens obtained from patients
nfected with different HCV genotypes. The other
roup, designated the genotype-specific group, is
omposed of peptides that immunoreacted with serum
pecimens obtained from patients infected with the
ame genotype as the genotypes from which these
eptides were derived. Peptides derived from all ge-
otypes were found in both groups, except for pep-
ides derived from genotype 6 since the genotyped
anel did not contain any member of this genotype.
Peptides from both groups were not uniformly distrib-
ted along region 5-1-1 (Table 1). Peptides from the
enotype-specific group were generally found within the
entral part of this region (1704–1732 aa), whereas pep-
ides from the genotype-independent group were pre-
ominantly clustered within the N-terminal part (1684–
715 aa). To a large extent, the distribution of invariant
mino acid positions along the protein chain of region
-1-1 (Fig. 1) coincided with the distribution of peptides
ith genotype-independent and genotype-specific anti-
enic activity. For example, region 1696–1711 aa, which
as spanned with cross-immunoreactive peptides (geno-
ype-independent peptides), contained 8 invariant posi-
ions of 13 found across the entire 5-1-1 region (Fig. 1).
onversely, the region 1712–1732 aa, which was
panned by peptides with genotype-specific activity, con-
ained only 2 such invariant positions. Finally, peptides
erived from the C-terminal part of region 5-1-1 were
ound to be mostly not immunoreactive (Table 1). In
imilar experiments, two types of major antigenic
pitopes at positions 1691–1708 aa and 1710–1728 aa
ere identified by using synthetic overlapping 9-mers
60 aa and location of synthetic peptides. Genotypes are shown within
sequence. Invariant positions in all sequences are shaded. Horizontal
resent synthetic peptides.1901–19
of theorresponding to the consensus amino acid sequences
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181NS4 ANTIGENIC EPITOPES OF HEPATITIS C VIRUSf HCV subtypes 1a, 1b, 2b, and 3a (Simmonds et al.,
993b). In concert with the observation made in the
resent study, this group of researchers showed that an
ntigenic epitope(s) at position 1691–1708 aa cross-im-
FIG. 3. Dendrogram showing relatedness of amino acid sequence
t the end of each branch. Genotypes and subtypes are identified
onventional units of relatedness of amino acid sequences calculat
nc., Madison, WI).unoreacted with antibodies to several HCV genotypes, ghereas an epitope(s) at position 1708–1728 aa tended
o immunoreact with antibodies to its own genotype
Simmonds et al., 1993b). These observations suggest
hat region 5-1-1 contains both genotype-specific and
ed from the region 5-1-1. Each sequence is identified by a number
jor branches of the dendrogram. The scale at the bottom shows
he program MegAlign from Lasergene software package (DNAStars deriv
at ma
ed by tenotype-independent antigenic epitopes.
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182 CHANG ET AL.enotype-independent antigenic epitopes of region
-1-1
Among 377 nonidentical peptides derived from region
-1-1, 159 peptides were found immunoreactive with se-
um specimens containing antibodies to more than one
CV genotype. As can be seen in Table 1, peptides 2, 3,
nd 4, spanning the region 1688–1715 aa, are the most
roadly immunoreactive. These peptides detected anti-
ody activity in 33–61% of anti-HCV-positive serum sam-
les obtained from patients infected with genotypes 1–5.
ineteen peptides derived from genotype 1 and 3 se-
uences immunoreacted with 10–11 specimens of the 18
embers of the genotyped panel (Table 2). All broadly
eactive genotype 1 peptides presented in Table 2 con-
ain the common sequence PDREVLYQEFDE (Fig. 1). Any
mino acid change within this sequence led to a slight
eduction in the breadth of peptide immunoreactivity (Fig.
, Table 1). For example, peptides 2, 3, and 4 derived from
equence 16 and 21, or from sequence 9 and 10, or 8 and
8, differ by only one amino acid (Fig. 1). However, this
ingle amino acid substitution resulted in a decrease in
he number of immunoreactive specimens from 10–11 to
–8 (Table 1). It is interesting to note that despite a
-amino-acid substitution in genotype 3a sequences
Fig. 1) within the sequence common among all broadly
mmunoreactive genotype 1 peptides (see above), pep-
ide 3 derived from all but one genotype 3a sequence
emonstrated strong immunoreactivity with 10 of 18
pecimens (Table 1). Peptides 2 and 4 from the genotype
a sequences demonstrated noticeably lower antigenic
eactivity (Table 1). Moreover, a slight change in the
rimary structure of peptides from Leu to Ile in peptide 3
rom sequence 57 (Fig. 1) reduced the immunoreactivity
f this peptide from 10 to 7 serum specimens (Table 1).
aken together, these observations suggest that the an-
FIG. 4. Dendrogram for the region 59 amino acid sequences (see
egend to Fig. 3).igenic reactivity of a broadly cross-reactive genotype 3a tpitope(s) from region 5-1-1 is more conformationally
ependent than the reactivity of the same epitope from
he genotype 1 epitope(s). An exception to this conclu-
ion may be observed for two genotype 3b peptides
Nos. 3 and 4). Despite two amino acid substitutions from
ys to Arg and from Glu to Gln relative to the genotype 3a
equences (Fig. 1), these peptides maintained their
road antigenic cross-reactivity (Table 1). It is conceiv-
ble that these two substitutions convert this antigenic
pitope(s) into a conformation that is less susceptible to
mino acid variations.
As can be seen in Table 2, broadly cross-reactive
eptides from the genotype-independent group demon-
trated immunoreactivity with antibodies to all of the
enotypes tested. Six serum specimens with antibodies
o genotypes 2, 3, and 4 did not react with the NS4
ntigen in the semiautomated dot blot immunoassay
Abbott Matrix, Abbott Laboratories). Three of these
pecimens were also not immunoreactive with any of the
ynthetic peptides shown in Table 2. Three other speci-
ens were weakly immunoreactive with only one or two
eptides. It is interesting to note that the genotype 3
pecimen 11, which was Abbott Matrix NS4-negative,
eakly immunoreacted with two genotype 1 peptides
nd did not react with any broadly cross-reactive geno-
ype 3 peptides. A somewhat different situation was
ound with genotype 1 specimens, all of which were
trongly Abbott Matrix NS4-positive (Table 2). However,
pecimen 2 did not immunoreact with any of the peptides
resented in Table 2. Specimen 3 weakly immunore-
cted with genotype 3 peptides only. Collectively, 19
eptides in the genotype-independent group may be
esignated broadly cross-reactive peptides. Each of
hese peptides immunoreacted with 10 to 11 serum
pecimens and taken together they could detect 78% of
he specimens tested (Table 2).
enotype-specific antigenic epitopes of region 5-1-1
As shown in Table 3, 46 of 377 peptides synthesized
or region 5-1-1 immunoreacted with serum specimens
ontaining antibodies to their own HCV genotype. Thus,
hese peptides constitute the genotype-specific group.
wenty-five genotype-specific peptides, which could im-
unoreact to more than half of the serum specimens
orresponding to their own types, were considered
trong genotype-specific peptides. For example, pep-
ides 6, 7, 8, and 10 from subtype 1a sequences demon-
trated strong genotype-specific immunoreactivity. It is
eculiar, however, that peptide 9, which significantly
verlaps with the sequences of peptides 8 and 10 (Fig.
), demonstrated genotype-independent antigenic reac-
ivity (Table 1). This peptide, derived from genotype 1
equences, cross-reacted with one genotype 5 serum
pecimen (data not shown). These findings suggest thathe region at position 1704–1738 aa of subtype 1a
183NS4 ANTIGENIC EPITOPES OF HEPATITIS C VIRUSTABLE 1
Antigenic Reactivity of Peptides Derived from Region 5-1-1
Note. White boxes indicate genotype-independent peptides; shaded boxes indicate genotype-specific peptides.
* The number of immunoreactive serum specimens.
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184 CHANG ET AL.equences spanning these 5 peptides contains at least 2
enotype-specific antigenic epitope and 1 genotype
ross-immunoreactive antigenic epitope. Similar conclu-
ions may be made for genotype 2 and 3 sequences. For
enotype 2, peptides 5 and 8 were found to be immuno-
eactive, while no antigenic reactivity was detected for
eptides 6 and 7 (Table 1). This finding suggests that the
egion at position 1700–1730 aa spanned with these 4
eptides contains at least 2 genotype-specific antigenic
pitopes. For genotype 3, peptides 6, 8, 9, 11, and 12
ere found to be immunoreactive with genotype 3 serum
pecimens (Table 1 and 3), peptide 7 cross-reacted with
enotype 1 sera (data not shown), and peptide 10 was
onimmunoreactive (Table 1). These findings suggest
hat genotype 3 sequences at position 1705–1747 aa
panned with these 6 peptides contain at least 3 geno-
ype-specific epitope and 1 genotype-independent anti-
enic epitope.
An analysis of the immunoreactivity of serum speci-
ens with synthetic peptides derived from region 5-1-1
f different sequences revealed that not all serum spec-
mens contained antibodies that can bind both genotype-
ndependent and genotype-specific peptides. Table 3
hows that serum specimens 1 (genotype 1), 13 (geno-
ype 4), and 18 (genotype 5) do not contain antibodies
hat could be detected with genotype-specific peptide
nd could be detected only by using genotype-indepen-
ent peptides. The opposite situation was observed for
erum specimens 2 (genotype 1) and 12 (genotype 3).
hese specimens immunoreacted with only genotype-
pecific synthetic peptides.
In conclusion, both genotype-specific and genotype-
ndependent peptides derived from region 5-1-1 immu-
oreacted with antibodies from two slightly different sub-
T
Antigenic Reactivity of Genotype-Indep
* Signal/cut-off values.ets of serum specimens. Altogether, peptides pre- sented in Tables 2 and 3 detected 17 of 18 serum
pecimens. Specimen 14 (genotype 4) was not immuno-
eactive with any of the synthetic peptides from region
-1-1, nor was it immunoreactive with the NS4 antigen
sed in the Abbott Matrix test (Tables 2 and 3). It is
mportant to note that 5 of 6 Abbott Matrix-negative
pecimens (except specimen 14) containing antibodies
o HCV genotypes 2, 3, and 4 were found to be immuno-
eactive with the appropriate genotype-specific peptides
Table 3). Therefore, anti-NS4 activity may be more reli-
bly detected in patients infected with different geno-
ypes when both genotype-specific and genotype-inde-
endent antigenic epitopes derived from region 5-1-1 are
ncluded as antigenic targets. At the same time, serum
pecimens that do not contain detectable genotype-spe-
ific antibodies, such as specimens 1, 13, and 18, pose
roblems for HCV serotyping and may be responsible for
ome cases of unidentifiable serotypes, which were re-
orted as untypable serum specimens in recently devel-
ped type-specific assays (Simmonds et al., 1993b; Bhat-
acherjee et al., 1995; Zhang et al., 1995).
mmunoreactivity of peptides derived from region 59
Among 66 peptides derived from region 59, represent-
ng 7 different sequences from HCV genotypes 1, 2, and
, 38 peptides were found to be immunoreactive. Pep-
ides 5, 6, and 7, derived from 5 sequences (1, 3, 4, 5, and
), detected anti-HCV antibodies in 10–16 serum speci-
ens each (Fig. 5). Overall immunoreactivity of peptides
erived from sequences 2 (genotype 3) and 6 (genotype
) was noticeably lower than for peptides from the other
equences (Fig. 5), while peptide 6, derived from se-
uence 6, was immunoreactive with 11 of the serum
t Peptides Derived from Region 5-1-1ABLE 2
endenpecimens. The average P/N ratios for the most immu-
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185NS4 ANTIGENIC EPITOPES OF HEPATITIS C VIRUSoreactive peptides from each sequence (except for se-
uence 2) varied from 45.1 to 79.8. Peptides 6 from
equence 3 (genotype 1) and 7 from sequence 1 (geno-
ype 3) were two of the most immunoreactive peptides
ound in this study. These peptides immunoreacted with
5–16 serum specimens with an average P/N values
qual to 68.8 and 79.8 for peptide 6 (sequence 3) and
eptide 7 (sequence 1), respectively. By combining these
wo peptides with peptide 5 from sequence 4 (genotype
), anti-HCV activity was detected in all serum speci-
ens used in this study (data not shown).
No genotype-specific antigenic reactivity was identi-
ied for any peptide derived from region 59. However,
ifferent serum specimens were found to be immunore-
ctive with a different number of peptides. The majority
T
Antigenic Reactivity of Genotype-Sp
* Signal/cut-off values.f serum specimens immunoreacted with peptides 14 to t3, whereas serum specimens 5 (genotype 1), 7 (geno-
ype 4), and 18 (genotype 5) immunoreacted with as few
s 8, 7, and 4 peptides, respectively. Anti-HCV activity in
era 1 (genotype 1) and 14 (genotype 4) was detected
nly with peptide 5 from sequence 4 (genotype 2) and
eptide 7 from sequence 1 (genotype 3). It is interesting
o note that specimen 14, which was not immunoreactive
ith any peptide derived from region 5-1-1 (see above),
as found to be immunoreactive with only peptide 7
sequence 1) derived from region 59.
Recently, additional sequences from region 59 were
ublished for HCV genotypes 4, 5, and 6 (Chamberlain et
l., 1997; Stuyver et al., 1994; Adams et al., 1997). Since
o significant sequence heterogeneity was found for
hese sequences (data not shown) and because no geno-
eptides Derived from Region 5-1-1ABLE 3
ecific Pype-specific immunoreactivity was identified for any
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186 CHANG ET AL.eptide derived from region 59 representing genotypes
–3, we did not pursue analysis of peptides from geno-
ypes 4–6.
eterogeneity of HCV NS4 antigenic epitopes
Analysis of 73 different amino acid sequences from 6
CV genotypes showed that the primary structure of
egion 5-1-1 is considerably variable. The range of se-
uence similarity was between 32.4 and 98.6%, an ob-
ervation previously reported (Simmonds, 1995). One
tudy, although based on a smaller subset of sequences
han reported in this paper, has shown that the NS4a
ucleotide sequence is only slightly more conserved
han the E1 sequence with evolutionary distances rang-
ng from 0.46 to 0.80 between major genotypes (Bhat-
FIG. 5. Reactivity of a panel of 18 serum specimens containing an
eptides derived from 7 different sequences of the region 59. Each bar
f 11 synthetic peptides derived from 1 of 7 sequences (see Figs. 2 anacherjee et al., 1995) compared to 0.43–0.85 for E1 (Bukh ot al., 1993) and much more conserved than core se-
uences with a range of evolutionary distances from 0.13
o 0.25 (Chan et al., 1992). Such significant heterogeneity
f the primary structure of the HCV NS4 protein has a
ubstantial effect on its antigenic properties. Several
tudies have shown that the first-generation enzyme
mmunoassay for the detection of anti-HCV activity,
hich was based on the c100-3 protein from genotype 1a
nd which comprises a substantial part of NS4, demon-
trated genotype-specific differences in serologic reac-
ivity (Nagayama et al., 1993; McOmish et al., 1993, 1994;
lonso et al., 1994; Chan et al., 1991; Dhaliwal et al., 1996;
ein et al., 1995, 1997). For example, 93% of patients
nfected with HCV subtype 1a and 79% with HCV subtype
b had detectable antibodies to C100-3 antigen, whereas
to HCV genotypes 1–5 (see Materials and Methods) with synthetic
shows the number of serum specimens immunoreactive with each set
r detail).tibodies
graphnly 34% of patients infected with HCV genotype 2 had
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187NS4 ANTIGENIC EPITOPES OF HEPATITIS C VIRUSetectable antibodies to C100-3 antigen (Nagayama et
l., 1993). Similar results demonstrating a lower immu-
oreactivity of protein 5-1-1 and C100-3 with serum spec-
mens obtained from patients infected with HCV geno-
ypes 2 and 3 were also observed by other groups of
esearchers (McOmish et al., 1993, 1994; Alonso et al.,
994; Chan et al., 1991; Dhaliwal et al., 1996; Zein et al.,
995, 1997).
Epitope mapping of the NS4 protein has revealed the
resence of linear antigenic epitopes that can be effi-
iently modeled with synthetic peptides of different sizes
Simmonds et al., 1993b; Bhattacherjee et al., 1995;
hudyakov et al., 1995). Analysis of the antigenic reac-
ivity of synthetic peptides derived from the NS4 consen-
us sequence of several genotypes allowed the identifi-
ation of two major genotype-specific antigenic regions
t positions 1691–1708 aa and 1710–1728 aa within re-
ion 5-1-1 (Simmonds et al., 1993b; Bhattacherjee et al.,
995). This finding, together with the identification of
enotype-specific antigenic epitopes within the core
Machida et al., 1992) and NS5 proteins (Zhang et al.,
994), was used for developing a multiple peptide assay
or serotyping HCV (Simmonds et al., 1993b; Bhattacher-
ee et al., 1995; Zhang et al., 1995).
The results reported in the present paper confirm the
bservations regarding the genotype-specific antigenic
eactivity of region 5-1-1 (Simmonds et al., 1993b) by
nalyzing a large number of synthetic peptides derived
rom 73 different sequences from 6 HCV genotypes. In
ddition, this paper reports new information regarding
he antigenic heterogeneity of region 59 peptides derived
rom 3 different genotypes. In a previous study on the
mmunoreactivity of the first antigenic region (1691–1708
a) (Simmonds et al., 1993b), only limited serological
ross-reactivity between different HCV types was de-
ected between 9-mer peptides. In our study, however, 17
eptides derived from essentially the same region at
osition 1688–1715 aa demonstrated broad serological
ross-reactivity by detecting antibodies to HCV geno-
ypes 1–5 from 10–11 serum specimens of 18 tested
Table 2). This discrepancy may be explained by differ-
nces in antibody specificity in serum specimens or in
he length of the peptides used (20-mer vs 9-mer). How-
ver, some less broadly reactive peptides, such as Nos.
and 3 derived from sequence 46 (genotype 1), peptide
from sequence 35 (genotype 1), or peptide 3 from
equence 68 (genotype 2) (see Fig. 1, Table 1), did show
ome degree of genotype-specific reactivity because
hey were more strongly immunoreactive with their own
ype of serum specimens (data not shown).
The amino acid sequences from region 59 are more
onserved than sequences from region 5-1-1 (Fig. 2).
ccordingly, essentially no genotype-specific antigenic
eactivity was detected with any peptide derived from
his region (data not shown). As shown previously
Khudyakov et al., 1995) and confirmed in this study, (egion 59 contains a very strong linear antigenic
pitope(s) that can be efficiently modeled with synthetic
eptides. By combining only 3 peptides from different
equences, 18 of 18 anti-HCV positive serum specimens
see above), 6 of which tested anti-NS4 negative by
atrix (Table 2 and 3), were detected. Five of these six
pecimens were also immunoreactive with genotype-
pecific peptides derived from region 5-1-1 (Table 3).
ne of these six, serum specimen 12, was indeterminate
ecause it immunoreacted with only the core antigen
data not shown). However, this specimen was strongly
mmunoreactive with some peptides from region 59 and
lso with some genotype-specific peptides from region
-1-1 (Table 3). These findings, along with the observa-
ion that some serum specimens were immunoreactive
ith only genotype-independent peptides among all the
eptides designed from region 5-1-1 (Table 2 and 3),
trongly suggest that carefully selected sequences from
oth NS4 genotype-specific antigenic epitopes and geno-
ype-independent antigenic epitopes from region 5-1-1
nd 59 may be used as antigenic targets for the devel-
pment of highly specific and sensitive diagnostic immu-
oassays for the efficient detection of HCV infections
rrespective of genotype.
MATERIALS AND METHODS
erum specimens
A genotyped panel of 18 anti-HCV-positive serum
pecimens was reposited in Boehringer Mannheim
GmbH, Penzberg, Germany). This panel includes spec-
mens containing antibodies to the HCV genotype 1 (n 5
), 2 (n 5 3), 3 (n 5 4), 4 (n 5 4), and 5 (n 5 2) confirmed
y restriction fragment length polymorphism (RFLP).
ourteen anti-HCV negative serum samples were ob-
ained from a collection of normal human blood donor
erum specimens reposited at the Centers for Disease
ontrol and Prevention (CDC, Atlanta, GA). The anti-HCV
tatus of all serum specimens was identified with the
econd-generation anti-HCV enzyme immunoassay (Ab-
ott Laboratories, Chicago, IL) and confirmed with a
emiautomated dot blot immunoassay (Abbott Matrix,
bbott Laboratories). All serum specimens in the panel
ested positive for HCV RNA by reverse transcription and
ested polymerase chain reaction (RT-PCR) (McOmish et
l., 1994). For the first-round PCR, CTGTGAGGAACTACT-
TCTT was used as sense prime and GTGCTCATGGT-
CACGGTCTACGAGACCT was used as antisense
rimer. For the second-round PCR, TTCACGCA-
AAAGCGTCTAG was used as sense primer and
ACTCGCAAGCACCCTATCAGGCAGT was used as an-
isense primer. The methods and conditions of RT-PCR
ere described in the paper from Simmonds’ groupMcOmish et al., 1994).
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188 CHANG ET AL.ynthetic peptide
In total, 377 20-mer peptides designed for region 5-1-1
nd 66 for region 59 were designed. All peptides were
ynthesized by FMOC chemistry (Barany and Merrifield,
980) on an ACT Model MPS 350 multiple peptide syn-
hesizer (Advanced Chemtech, Louisville, KY). The purity
f all peptides were investigated by reverse-phase high-
erformance liquid chromatography. The identity of in-
ufficiently pure peptides was checked by electrospray
ass spectrometry coupled to analytical reverse-phase
iquid chromatography. Impure peptides were resynthe-
ized or purified by preparative reverse-phase chroma-
ography.
nzyme immunoassay
Briefly, peptides were adsorbed on microtiter plates
Immulon II, Dynatech Industries, Inc., McLean, VA) at 1
g per well overnight. Serum samples were diluted 1:100
r 1:200 and incubated with peptides for 1 h at 37°C.
oat anti-human immunogloblin G (IgG) conjugated with
orseradish peroxidase diluted 1:4000 (Biosource Inter-
ational, Camarillo, CA) was then incubated with the
lates for 1 h at 37°C. Between each step, the wells were
ashed five times with 0.01 M phosphate-buffered sa-
ine/Tween 20, pH 7.4–7.6. A colormetric reaction was
eveloped by adding o-phenylenediamine z 2HCl (OPD)
o the plates and stopped with sulfuric acid after a 7- to
0-min incubation in the wells. The optical density (OD)
f the reaction was measured at 493 nm. The peptides
ere evaluated by calculating a P/N value, where P is
he OD value when the peptide was incubated with
CV-positive serum, and N is the OD value when the
eptide was incubated with HCV-negative serum. Since
ll peptides showed very low background when they
ere incubated with 14 HCV-negative serum samples
rom normal human blood donors, a mean N value of
eptides tested within each day was used in the analy-
is. The mean negative value was 0.013 6 0.003 stan-
ard deviation (SD). A peptide was considered positive
hen the OD value was greater than 0.1 and the P/N ratio
as greater than 5.0. A P/N ratio equal to 5.0 was
quivalent to the mean OD value of negative control
erum samples plus 5–10 standard deviations of the
ean. To compare results with the NS4 antigen on MA-
RIX (Abbott Laboratories), a single/cut-off (S/C) value
as developed. The C value was the mean OD value of
egative control serum samples plus 3.5 standard devi-
tions of the mean.
omputer-assisted sequence analysis
Amino acid sequence analysis was performed by us-
ng the program MegAlign from Lasergene software
ackage (DNAStar Inc., Madison, WI).ccession numbers of the HCV sequences
GenBank accession numbers for the amino acid se-
uences of the region 5-1-1 (1684–1750 aa) used in this
tudy are as follows: 1, D10750; 2, U14276; 3, M84754; 4,
14245; 5, U14253; 6, D30613; 7, U14263; 8, U14252; 9,
96362; 10, U14273; 11, U14268; 12, U14265; 13, U14265;
4, M58335; 15, U14257; 16, U14254; 17, U14243; 19,
14248; 20, D11168; 21, D11168; 22, U14247; 23, U14271;
4, U14280; 25, U14242; 26, U14274; 27, L02836; 28,
10934; 29, U14240; 30, U26687; 31, U14249; 32, U14246;
3, U01214; 34, U14278; 35, D11397; 36, U14267; 37,
14266; 38, D63857; 39, M86766; 40, U14259; 41, U14262;
2, U14272; 43, M32084; 44, M60220; 45, D10749; 46,
14279; 47, U14258; 48, U14270; 49, D14853; 50, M67463;
1, U14261; 52, U14260; 53, D01103; 54, L29579; 55,
14269; 56, D14602; 57, D14600; 58, X76918; 60, D17763;
1, D28917; 62, D49374; 63, U14277; 64, D10988; 65,
14114; 66, D14110; 67, U14255; 68, D00944; 69, D14112;
0, D11353; 71, U14250; 72, Y11604; and 73, Y12083.
GenBank accession numbers for the amino acid se-
uences of region 59 (1901 to 1960) are as follows: 1,
49374; 2, D28917; 3, U01214; 4, D00944; 5, D10988; 6,
16362; and 7, U45476.
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